Drugs
Improve ‘Substantial Effectiveness’ Draft Guidance: Stakeholders
Four stakeholders are suggesting ways FDA could improve its draft guidance on substantial evidence of effectiveness for human drug and biological products. The Center for Science in the Public Interest (CSPI) says it “opposes any shift in the regulatory standard to a one-trial default….” While the draft does not